Steatohepatitis/Metabolic Liver Disease News

BOSTON — Metabolic dysfunction-associated steatohepatitis is currently the most common indication for liver transplantation in patients with hepatocellular carcinoma, increasing from 10% in 2013 to 31% in 2022, according to a presenter.

BOSTON — An intensive, advanced practice provider-guided weight loss program helped patients with metabolic dysfunction-associated steatotic liver disease achieve statistically significant weight loss vs. standard of care.

BOSTON — Researchers recommended the FibroScan-aspartate aminotransferase score as a noninvasive biomarker to stratify patients at risk for metabolic dysfunction-associated steatohepatitis, when used with different cutoff points for HbA1C.

BOSTON — A new model forecasted a “substantial clinical burden” of metabolic dysfunction-associated steatotic liver disease in the next 30 years, including twice as many cases of liver cancer and triple the need for liver transplantation.

BOSTON — Food insecurity in adolescents is “very tightly associated” with metabolic dysfunction-associated steatotic liver disease, which may result from not being able to eat or purchase a balanced meal, according to a researcher.

VANCOUVER, British Columbia — Despite recent changes in nomenclature for metabolic dysfunction-associated steatotic liver disease, an expert here noted that clinical pathways largely remain the same and require reinforcing.

VANCOUVER, British Columbia — A diagnosis of and treatment for alcohol use disorder after a hospital encounter for alcohol-associated liver disease correlated with lower odds for mortality, according to a presenter here.

VANCOUVER, British Columbia — Insulin resistance, HbA1c and waist circumference represent independent risk factors for metabolic dysfunction-associated steatotic liver disease among lean patients, according to data presented here.

Individuals with low birthweight or born small for gestational age were significantly more likely to develop nonalcoholic fatty liver disease later in life, with additionally higher odds for more severe NAFLD, according to data at UEG Week.

Subcutaneous pegozafermin at weekly and biweekly doses improved fibrosis at 24 weeks vs. placebo among patients with biopsy-confirmed nonalcoholic steatohepatitis, supporting the therapy’s advancement to phase 3 development, data showed.